Hikma signs licensing agreement to bring innovative oncology treatment to MENA
Hikma Pharmaceuticals PLC announces an exclusive licensing agreement with pharmaand GmbH to commercialise rucaparib across the Middle East and North Africa (Petra photo)
AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria.
The agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region, the Jordan New Agency, Petra, reported.
Rucaparib, marketed as Rubraca, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells.
This mechanism makes rucaparib an 'important' treatment option for patients battling ovarian cancer, the eighth most common cancer in women globally, and prostate cancer, the fourth most common cancer worldwide and the second most common cancer in men.
Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA).
Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.'
'This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day,' Darwazah added.
As the company's first innovative small-molecule oral therapy in oncology approved by the USFDA and EMA, this partnership boosts Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes, he noted.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Jordan News
15-05-2025
- Jordan News
Remembering Samih Darwazah
اضافة اعلان Ten years have passed since the passing of Samih Darwazah, God bless his soul, yet his legacy grows more relevant with time, one that never dies, like mathematical rules: they are indispensable to tackle problems yesterday, now and after a million story is not just the tale of a self-made businessman who built a global pharmaceutical empire—it is the story of a man who believed in the power of vision, integrity, and nation-building through industry. His mind was wired for depth, with a belief in man's ability to turn challenges into opportunities. When it came to ambition, the sky was his in Nablus in 1930 and educated at the American University of Beirut and later the St. Louis College of Pharmacy in Saint Louis, Missouri, in the United States, Darwazah returned to the region at a time when few dared to dream of industrial self-sufficiency. In 1978, he founded Hikma Pharmaceuticals in Amman with a clear goal: to manufacture high-quality, affordable medicine for the Arab world and beyond. His challenge, as he once said, was to prove that medicine made in Jordan could be of a quality that equals, or even surpasses, "foreign" pharma started as a modest operation would, in time, grow into a multinational company operating in more than 50 countries. In 2005, the company floated on the London Stock Exchange, and in 2015, it entered the FTSE 100 Hikma was never just about pharmaceuticals. Under Darwazah's leadership, it became a model for what Arab entrepreneurship could look like—rooted in values, guided by long-term thinking, and grounded in a deep commitment to people. He defied the narrative that the region must rely on imports and external expertise. From the very beginning, he assembled a team of savvy pharmacists and gave every one of his employees the opportunity to pursue their education to grow professionally. That plan was so successful that some of these staff members became independent entrepreneurs, proud that they were graduates of the Hikma Samih Darwazah, whose unlimited dreams are still pursued by his two sons, Said and Mazen, placed Jordan on the map as a country capable of producing world-class medication, with a skilled workforce and a competitive, export-ready set him apart was not only his visionary business sense, but also his principled approach. Colleagues and competitors alike always spoke of his "clean hands"—a phrase that captures both his ethical leadership and the transparency with which he conducted his contributions extended beyond boardrooms and balance sheets. He was a generous philanthropist who invested in education, particularly in underserved communities. His establishment of the all-girls state-of-the-art school in the Shobak region, among other initiatives, was rooted in his belief that opportunity begins with education—and that empowering women was essential to building a more just and prosperous he championed local industry not only out of nationalism, but also because he believed that dignity and independence are inseparable from economic self-reliance. That belief resonated deeply with a generation of Jordanian professionals who saw in him not only a role model, but also a source of national and Arab we mark the tenth anniversary of his passing, we need to remind ourselves that his real legacy lies in the enduring relevance of his vision. In a time of global uncertainty, we find ourselves returning to the same questions he answered with action decades ago: Can the Arab world produce? How can we realize industrial progress and harness it to serve people? The answers can be found through a glimpse into his remarkable Darwazah's example continues to inspire a generation of entrepreneurs, scientists, and policymakers who believe that excellence, ethics, and impact should go hand in hand to owe it to his memory not merely to celebrate him—but to carry forward the noble values he embodied. After all, in humanity's journey, heroes serve as our best examples.###
Jordan News
28-04-2025
- Jordan News
Royal Jordanian records higher revenues, reduced losses, improved performance - Jordan News
Royal Jordanian records higher revenues, reduced losses, improved performance Royal Jordanian Airlines (RJ) recorded higher revenues, improved operating profits, and reduced post-tax losses in 2024, according to the company's latest financial results. اضافة اعلان RJ announced that its operating revenues rose to JOD 745.6 million, compared to JOD 733.2 million in 2023, while its operating profit reached JOD 11.8 million, up from JOD 3.2 million the previous year, reflecting an increase of more than 260 percent. Post-tax losses dropped to JOD 3.5 million, compared to JOD 8.7 million in 2023, marking a 59 percent decline. The company attributed these positive indicators to continuous efforts to control costs, enhance performance efficiency, and boost operational flexibility despite highly complex regional conditions. The results were announced during the company's ordinary and extraordinary general assembly meetings, held on Sunday via videoconference, chaired by Saeed Darwazah, Chairman of the Board of Directors, and attended by Samer Majali, Vice Chairman and Managing Director. The meetings discussed the Board of Directors' report on RJ's activities and outcomes for the fiscal year 2024, as well as the plan for 2025. The auditors' report, annual balance sheet, and profit and loss account were also reviewed and approved by the General Assembly. Darwazah stressed that Royal Jordanian would continue to advance toward achieving its strategic goals despite the ongoing challenges posed by regional and international developments, including the repercussions of the wars on Gaza and Lebanon and broader political and economic fluctuations affecting the aviation sector and travel to and from Jordan. He emphasized that RJ has maintained its pivotal role in ensuring Jordan's connectivity with the outside world, despite the regional crises. Darwazah recalled similar contributions by RJ during critical periods in history, such as the air blockade on Iraq and the COVID-19 pandemic, highlighting the airline's commitment to fulfilling its national duty under all circumstances. For his part, Majali said that Royal Jordanian in 2024 pursued operational and financial growth, striving to enhance its performance across key indicators. He noted that the airline transported approximately 3.7 million passengers during the year, a 4 percent increase compared to 2023, and maintained a strong flight punctuality record, achieving an 88 percent on-time departure rate within 15 minutes. Majali further noted that RJ launched direct flights to new destinations, including London Stansted, Manchester, Moscow, Berlin, and Tripoli. He highlighted that the airline's fleet modernization program progressed with the delivery of five Embraer E2 aircraft in 2024, and 16 additional aircraft including 14 Airbus aircraft and two Embraer E2 aircraft expected by the end of 2025. He underscored that the financial results validate the soundness of RJ's approach in addressing challenges and restoring financial balance. The airline remains committed to a comprehensive reform plan aimed at restructuring costs, diversifying revenues, expanding its route network, enhancing air cargo operations, and investing in support services. Majali also pointed to RJ's focus on human capital development, with the company implementing training and institutional programs to qualify national competencies. He added that Royal Jordanian aims to expand its fleet to 41 aircraft by 2028, accompanied by a clear strategy to ensure the readiness of qualified human resources in line with Civil Aviation Regulatory Authority standards. The expansion strategy, Majali noted, would enhance the airline's ability to meet future growth requirements while maintaining its commitment to corporate social responsibility and sustainability in the aviation sector. Petra
Jordan Times
09-04-2025
- Jordan Times
Hikma signs licensing agreement to bring innovative oncology treatment to MENA
Hikma Pharmaceuticals PLC announces an exclusive licensing agreement with pharmaand GmbH to commercialise rucaparib across the Middle East and North Africa (Petra photo) AMMAN — Hikma Pharmaceuticals PLC (Hikma) on Wednesday announced an exclusive licensing agreement with pharmaand GmbH (pharma&), a global pharmaceutical company based in Vienna, Austria. The agreement grants Hikma exclusive rights to commercialise rucaparib across the Middle East and North Africa (MENA) region, the Jordan New Agency, Petra, reported. Rucaparib, marketed as Rubraca, is an innovative small-molecule oral therapy designed to inhibit poly (ADP-ribose) polymerases (PARPs), a family of proteins critical to DNA repair in cancer cells. This mechanism makes rucaparib an 'important' treatment option for patients battling ovarian cancer, the eighth most common cancer in women globally, and prostate cancer, the fourth most common cancer worldwide and the second most common cancer in men. Rucaparib has received regulatory approval from the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA). Hikma Executive Vice Chairperson and President of MENA Mazen Darwazah said: "We are pleased to add rucaparib, an innovative oncology treatment, to our growing oncology portfolio in MENA.' 'This agreement is a major step to further enhance patients' access to life-changing treatments and address critical medical needs across the region. By strengthening our oncology portfolio, we reaffirm our commitment to providing advanced cancer treatments and supporting our purpose of putting better health within reach, every day,' Darwazah added. As the company's first innovative small-molecule oral therapy in oncology approved by the USFDA and EMA, this partnership boosts Hikma's promise of providing better access to life saving treatment options and its commitment to improving patient outcomes, he noted.
